About Us   |   Contact Us   |  
Submission  

The Spread of 𝛽-Lactamases and Extended Spectrum 𝛽-Lactamase Enzymes among Bacteria: A Threat to Effective Health Care Delivery

DOI : https://doi.org/10.36349/easjbg.2022.v04i01.002
PDF
HTML
XML

Antibiotic discovery continue to play a critical role in disease containment. Misuse and overuse of these drugs are the main drivers in the development of drug resistant pathogens. The World Health Organisation has declared that Antimicrobial resistance is one of the top 10 global public health threats facing humanity. There is the fears that if nothing is done, it might end the antibiotic era soon. In 2017 alone, over 9000 human deaths were caused by ESBL-producing Enterobacteriaceae in the USA. The ability of bacteria to develop newer strategies to acquire and disseminate resistance, can be traced as far back to 1940s when (R-factor) plasmid mediated antibiotic resistance was observed. They become resistant via the production of 𝛽-Lactamases and ESBLs enzymes which inactivate or modify antibiotics. Extended Spectrum 𝛽-Lactamases are enzymes whose rates of hydrolysis of the extended-spectrum 𝛽-Lactam antibiotics are >10 % than that for benzylpenicillin. Some bacteria may produce multiple ß-lactamases, which may reduce the effectiveness of ß-lactam/ ß-lactamase inhibitor combinations. These enzymes are susceptible to inhibition by 𝛽-Lactam inhibitors such as clavulanic acid, tazobactam, or sulbactam but have no hydrolytic activity against cephamycins and carbapenems. The production of acquired 𝛽-Lactamase and ESBL makes the choice of antibiotic treatment of infections caused by Gram-negative bacteria very limited, these have been the major causes of treatment failures, outbreaks of both community and hospital acquired infections, surgical failures, long hospital stay and huge economic losses, which continue to claim uncountable lives, especially in Nigeria and Africa where the health system are weak. The emergence of drug resistannt strains may be minimized by maintaining high levels of the drug in the tissues to inhibit mutants, administering two drugs that do not give cross-resistance, and by limiting the use of valuable second line ‘reserve drugs’ such .....

TOP EDITORS

OPEN ACCESS JOURNALS

Dr. Afroza Begum

Lecturer, Dept. of Pharmacology and Therapeutics, Shaheed Monsur Ali Medical College & Hospital, Uttara, Dhaka-1230, Bangladesh

BEST AUTHOR

Of The Month

TRACK YOUR ARTICLE

Enter the Manuscript Reference Number (MRN)
Get Details

Contact us


EAS Publisher (East African Scholars Publisher)
Nairobi, Kenya


Phone : +91-9365665504
Whatsapp : +91-8724002629
Email : easpublisher@gmail.com

About Us


EAS Publisher (East African Scholars Publisher) is an international scholar’s publisher for open access scientific journals in both print and online publishing from Kenya. Its aim is to provide scholars ... Read More Here

*This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2020, All Rights Reserved | SASPR Edu International Pvt. Ltd.

Developed by JM